ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Connecticut » Hematology Oncology

Top Hematology Oncology Prescribers in Connecticut

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
PAUL DEKKER MD

Hematology Oncology

4,703

$641K

341
297 are 65+

0%
patients receiving schedule two controlled substances

Avg: 14%

4%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 21%

$136
Average prescription price

Avg: $435

HERVEY WEITZMAN MD

Hematology Oncology

3,554

$296K

196
163 are 65+

8%
patients receiving schedule two controlled substances

Avg: 14%

9%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

33%
prescriptions for brand name drugs

Avg: 21%

$83
Average prescription price

Avg: $435

STEPHEN FIRSHEIN MD

Hematology Oncology

2,239

$486K

264
243 are 65+

0%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 21%

$217
Average prescription price

Avg: $435

ROBERT BURD MD

Hematology Oncology

1,793

$159K

147
140 are 65+

0%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 21%

$89
Average prescription price

Avg: $435

EDWARD DUDA MD

Hematology Oncology

1,721

$871K

196
165 are 65+

21%
patients receiving schedule two controlled substances

Avg: 14%

6%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

29%
prescriptions for brand name drugs

Avg: 21%

$506
Average prescription price

Avg: $435

JOSEPH BOWEN MD

Hematology Oncology

1,495

$890K

219
186 are 65+

15%
patients receiving schedule two controlled substances

Avg: 14%

9%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 21%

$596
Average prescription price

Avg: $435

MANDEEP DHAMI MD

Hematology Oncology

1,437

$292K

278
220 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 21%

$203
Average prescription price

Avg: $435

KERT SABBATH MD

Hematology Oncology

1,395

$1.03M

209
185 are 65+

21%
patients receiving schedule two controlled substances

Avg: 14%

7%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 21%

$740
Average prescription price

Avg: $435

ROBERT COOPER M.D.

Hematology Oncology

1,393

$314K

170
156 are 65+

16%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 21%

$225
Average prescription price

Avg: $435

TODD ALEKSHUN M.D.

Hematology Oncology

1,367

$874K

145
126 are 65+

17%
patients receiving schedule two controlled substances

Avg: 14%

9%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

29%
prescriptions for brand name drugs

Avg: 21%

$640
Average prescription price

Avg: $435

DAVID WITT M.D.

Hematology Oncology

1,307

$1.67M

153
125 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

33%
prescriptions for brand name drugs

Avg: 21%

$1279
Average prescription price

Avg: $435

ROBERT LEVY M.D.

Hematology Oncology

1,274

$679K

165
138 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

8%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 21%

$533
Average prescription price

Avg: $435

JIE YANG M.D., PH.D.

Hematology Oncology

1,241

$772K

152
115 are 65+

20%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

29%
prescriptions for brand name drugs

Avg: 21%

$622
Average prescription price

Avg: $435

DEBRA BRANDT D.O.

Hematology Oncology

1,191

$395K

146
120 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 21%

$331
Average prescription price

Avg: $435

DINESH KAPUR MD

Hematology Oncology

1,183

$311K

155
130 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

8%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 21%

$263
Average prescription price

Avg: $435

ANCA BULGARU MD

Hematology Oncology

1,177

$431K

152
125 are 65+

19%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 21%

$366
Average prescription price

Avg: $435

RENUKA DULALA MD

Hematology Oncology

1,154

$309K

179
146 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 21%

$267
Average prescription price

Avg: $435

NEAL FISCHBACH MD

Hematology Oncology

1,151

$694K

159
136 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

8%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 21%

$603
Average prescription price

Avg: $435

DONALD BOYD M.D.

Hematology Oncology

1,131

$109K

132
116 are 65+

8%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

31%
prescriptions for brand name drugs

Avg: 21%

$96
Average prescription price

Avg: $435

GLEN REZNIKOFF M.D.

Hematology Oncology

1,098

$688K

160
132 are 65+

19%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 21%

$626
Average prescription price

Avg: $435

BRIAN BYRNE M.D.

Hematology Oncology

1,072

$766K

130
106 are 65+

23%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 21%

$714
Average prescription price

Avg: $435

MICHAEL COHENURAM M.D.

Hematology Oncology

1,038

$437K

155
138 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

7%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 21%

$421
Average prescription price

Avg: $435

ROBERT KLOSS M.D.

Hematology Oncology

1,023

$631K

147
126 are 65+

19%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 21%

$617
Average prescription price

Avg: $435

GERARD FUMO DO

Hematology Oncology

980

$145K

147
134 are 65+

10%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 21%

$148
Average prescription price

Avg: $435

JERRY MALEFATTO MD

Hematology Oncology

966

$609K

148
131 are 65+

26%
patients receiving schedule two controlled substances

Avg: 14%

11%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 21%

$631
Average prescription price

Avg: $435

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank